[Skip to Content]
[Skip to Content Landing]
Article
March 1996

Long-term Follow-up of Non-HIV Kaposi's Sarcoma Treated With Low-Dose Recombinant Interferon Alfa-2b

Author Affiliations

From the Departments of Dermatology (Drs Costa da Cunha, Lebbé, Rybojad, and Morel), Virology (Drs Agbalika and Ferchal), Immunology (Dr Rabian), and Histology (Dr Vignon-Pennamen) and Laboratory of Pharmacology (Dr Calvo), Hôpital Saint Louis, Paris, France.

Arch Dermatol. 1996;132(3):285-290. doi:10.1001/archderm.1996.03890270061008
Abstract

Background and Design:  We reviewed the follow-up of 16 patients with Kaposi's sarcoma not related to human immunodeficiency virus (13 with classic Kaposi's sarcoma and three with endemic Kaposi's sarcoma; median age, 58 years) treated by low-dose recombinant interferon alfa-2b (5 million U three times weekly for at least 6 months).

Results:  One patient had a complete response, nine had a major response, three had stable disease, and one had a minor response. Visceral disease stabilized and symptoms improved in three patients. Limited relapse was noted in four patients after withdrawal of interferon.

Conclusion:  Our results confirm the efficacy and safety of low-dose recombinant interferon alfa-2b in the longterm treatment of both cutaneous and visceral lesions of Kaposi's sarcoma not related to human immunodeficiency virus.(Arch Dermatol. 1996;132:285-290)

×